The Health and Care Bill has now been considered by both Houses of Parliament and the final stage is for the Commons to consider later this month the amendments which have been made in the Lords.

The Health and Care Bill went through Report Stage in the House of Commons on 22 November. This article provides a Q&A update on the debates that took place.

The Health and Care Bill had its Second Reading in the House of Commons on 14 July and is expected to become law in early 2022. This article explains the main purposes of the Bill and the potential implications for the life sciences industry.

The consultation of NICE methods in November 2020 was the first reassessment since 2013 and was widely welcomed. In February 2021, NICE began a review of the health technology evaluation processes. This article examines key issues related to each review and MAP’s response.

The conclusion of the Northern Ireland Protocol will have a direct effect on the life science industry who have current or potential sales to Northern Ireland.This article gives an overview of the Protocol and answers some of the key questions that have arisen in recent weeks.

Since the 2016 Brexit vote, there has been considerable uncertainty around the future of drug and medtech regulation in the UK. This article explores the potential routes towards a mutual recognition agreement and how this could be achieved through representation by the life sciences industry.

The New NHS White Paper on reforming the NHS, Integration and Innovation: working together to improve health and social care for all, which was foreshadowed in MAP’s blog on 9 February, was published on 11 February.